Business
Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell
Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technologyTUCSON, Ariz., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that it will ring the Opening
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gcgpu3t6z4ZWVpSIwIEbWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a","width":300,"height":75}},"lazy":false},{"type":"text","content":"Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technology","length":172,"tagName":"p"},{"type":"text","content":"TUCSON, Ariz., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that it will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking the Company’s transition to the public markets and its continued commitment to advancing total artificial heart therapy for patients with end-stage heart failure.","length":556,"tagName":"p"},{"type":"text","content":"“We are proud to mark Picard Medical’s transition to a newly public company,” said Patrick NJ Schnegelsberg Chief Executive Officer of Picard Medical. “Our technology has supported patients worldwide and becoming a public company strengthens our ability to advance our artificial heart platform including the fully implantable Emperor system. This marks an important next phase as we build on decades of clinical leadershippioneering the world’s first life-sustaining total artificial heart, advancing our next-generation technology and creating long-term value.”","length":563,"tagName":"p"},{"type":"text","content":"About Picard Medical and SynCardia","length":34,"tagName":"p"},{"type":"text","content":"Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynC...